Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Pancreatic Cancer × nimotuzumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 12 Esophageal Squamous Cell Carcinoma 8 Esophageal Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 6 Uterine Cervical Neoplasms 5 Pancreatic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 2 Recurrence 2 Pancreatic cancer, adult 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Diffuse Intrinsic Pontine Glioma 2 Uterine Cervical Dysplasia 1 Squamous Cell Carcinoma of Anal Canal 1 Penile Neoplasms 1 Pancreatic Cancer Resectable 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Meningeal Carcinomatosis 1 Hypopharyngeal Neoplasms 1 HCC 1 Glioma 1 Glioblastoma 1 Esophageal 1 Carcinoma, Squamous Cell 1 Carcinoma 1 Brain Neoplasms 1 Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 5 Albumin-Bound Paclitaxel 4 130-nm albumin-bound paclitaxel 4 Taxes 3 S 1 (combination) 3 Drug Therapy 2 toripalimab 1 nimotuzumab 1 irinotecan sucrosofate 1 gimeracil 1 envafolimab 1 endostar protein 1 cabiralizumab 1 apatinib 1 Tegafur 1 Radiosurgery 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Immunotherapy 1 IMM-101 1 Fluorouracil 1 Endostatins 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06422156 2024-05-20

Nim-PC-28

Peking University Third Hospital

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡